Antibiotic resistance in Helicobacter pylori infection
|
|
- Duane Briggs
- 6 years ago
- Views:
Transcription
1 Antibiotic resistance in Helicobacter pylori infection Francis Megraud haboratoire de Bacteriologie, Hopital Pellegrin, Bordeaux, France Resistance to antibiotics is considered as the primary reason for failure of eradication therapies. Resistance to clarithromycin is due to a decrease in binding to the ribosomes associated with a point mutation on the 23S rrna. Its rate in Europe varies from 0-15%, with 5% in the UK. The resistance influences dramatically the success of the treatments. Resistance to metronidazole is due to a lack of reduction of this compound whose genetic basis is still unknown. The resistance rate in Europe varies from 10-50%, with 25% in the UK. It influences the success of treatments to a lesser extent than clarithromycin resistance. The initial eradication treatment can be prescribed without testing for susceptibility and must include a combination of two antibiotics, while stressing the importance of compliance to the patient. In case of failure, susceptibility testing must be performed. Few data are currently available on alternative therapeutic strategies when H. pylori is resistant to both clarithromycin and metronidazole. Despite the fact that the optimal treatment for Helicobacter pylori infection has not been found, there are several combinations of drugs which can cure the infection in up to 80-90% of cases 1. There are several possible explanations for failure, such as a lack of compliance from the patient, but the main reason to date seems to be the occurrence of strains which are resistant to the antibiotics used 2. Among the compounds recommended for eradication of H. pylori, resistance occurs frequently with macrolides and nitroimidazoles but never with amoxicillin and tetracycline, although some anecdotal reports exist for the latter two (Table 1). This review will present current data concerning the mechanisms and the epidemiology of the resistance and consider ways to deal with this problem in clinical practice. Correspondence to Prof. Resistance mechanisms Laboratoire de Resistance to macrolides 'pellegrin, Macrolides are a group of antibiotics with a lactone ring of which Bordeaux cedex. France erythromycin is the leader. These antibiotics are administered orally, British Medical Bulletin 1998;54 (No. 1): O The British Council 1998
2 Helicobacter infection Table 1 MIC of different antibiotics on susceptible and resistant strains of H. pylori (mg/l) Amoxicillin Clarithromycin Metronidazole Tetracycline Ciprofloxacin Susceptible strains Resistant strains 4-64 >8 >2 they diffuse well in tissue, have a narrow spectrum and limited side effects. They are used to treat H. pylori infection in association with a second antimicrobial agent, either amoxicillin or a nitroimidazole compound, and an antisecretory drug. The most attractive compound to date is clarithromycin because it has the best efficacy in vitro. It is moderately affected by a decrease in ph, and good concentrations can be obtained in gastric mucosa. Once macrolides have penetrated into the bacterial cell, they bind tightly to ribosomes where protein synthesis takes place. The exact site of action is the peptidyl transferase loop of domain V of the 23S ribosomal RNA. In the event of resistance (MIC > 2 mg/l), there is a decreased affinity between ribosomes and clarithromycin 3. This property has been found to be associated with a point mutation in the 23S rrna gene in position 2143 (formerly 2058 in the Escherichia coli nomenclature) and 2144 (formerly 2059) 4. This result has been confirmed by others including studies on European strains 3 " 5 ' 6. The mutation is essentially a transition A >G but may be a transversion A»C in position 2143 in some cases 7. Detection of this mutation is possible after PCR using adequate primers amplifying part of the 23S rrna gene followed by sequencing or restriction with the enzymes Bsal (A2143G) and Bbsl (A2144G) but not A2143C. Recently, methods based on hybridization of the amplified products have been proposed, such as the PCR-oligonucleotide ligation assay*. Resistance to nitroimidazoles Metronidazole and tinidazole are the compounds in this class used to treat H. pylori infection. Cross resistance between these two drugs exists. The essential differences between them relate to their pharmacodynamics and safety profiles. To be active, metronidazole must penetrate into the bacteria. Subsequently, the NO 2 group of the nitroimidazole compound is reduced to form a hydroxylamine derivative. The reduced product causes damage to the DNA thereby causing cell death. 208 British Medical Bulletin 1998;54 (No. 1)
3 Antibiotic resistance Smith and Edwards studied drug uptake and the rate of cell killing of metronidazole against H. pylori and found it dependent upon the relative oxygen tension of the environment and the cell density, both of which determine the redox conditions of the media 9. These results are in agreement with the work of Cederbrant et al who showed diat in vitro metronidazole resistance could disappear when the strains were incubated anaerobically for a few hours before growth The low redox potential thus achieved led to an increased reduction of metronidazole, the active compound generated. The mechanism which renders the metronidazole resistant strains of H. pylori susceptible after a short anaerobic incubation is not yet known. The activation of an anaerobic metabolic pathway which does not function under microaerobic conditions could be the cause and would also explain the apparent non-stable resistance 12, since the atmosphere of incubation is not fully controlled during subculture of the strains. The genetic mechanism which underlines the resistance is not yet known 13 and, therefore, a molecular detection is not possible. Resistance to fluoroquinolones While fluoroquinolones are not routinely included in current regimens used to treat H. pylori infection, ciprofloxacin is sometimes used in the event of resistance to previously employed compounds. Fluoroquinolones interfere with DNA gyrase, an enzyme acting on the supercoiling of DNA during cell replication. In one study, resistance was found associated with four groups of point mutations in the gyra gene 14. A cross resistance also exists for this group of compounds. Resistance to tetracydines While currently not used extensively, tetracyclines are a component of the bismuth-based triple therapy regimen which was recommended in 1990 to treat H. pylori infection. Their site of action is the ribosome. It is thought that H. pylori does not acquire resistance to tetracyclines. However, this conception must be reconsidered following a recent description of a resistant strain in Australia 15. More information is needed, particularly with regards to the mechanism of action. Resistance to $-lactams Amoxicillin is the pmactam most commonly used in the regimens aiming to eradicate H. pylori. One might ask why H. pylori has not acquired resistance to this drug while, during more than 20 years, tons of amoxicillin have been used. British Medical Bulletin 1998;54 (No. 1) 209
4 Helicobacter infection The main mechanism of resistance in this group is linked to the production of P-lactamase, a resistance commonly found in Gramnegative bacilli and staphylococci. It seems that the H. pylori restriction enzymes do not allow the introduction of exogenous DNA from phylogenetically distant bacteria. Moreover, the possible contacts between H. pylori and these bacteria are most likely to be limited unless one believes that H. pylori can multiply in the intestine. Nevertheless, P- lactamase genes can theoretically be transferred to H. pylori. A second mechanism of resistance is a modification of the target, i.e. the penicillin binding proteins. Several of them may be present in H. pylori. It is possible that, if a resistance occurs in the future, it will be by this mechanism, as was the case with Streptococcus pneumoniae in recent years. In this case, the levels of resistance are usually relatively low. MICs of amoxicillin against H. pylori are usually low ( 0.03 mg/1). It is, however, possible to find strains with MICs 10 times higher ( mg/1) which warrant further study. The small number found in clinical trials does not allow an association between these strains and treatment failure to be detected. Furthermore, Dore et al recently reported tolerance to amoxicillin, however, this phenomenon seems difficult to maintain in subcultures 16. For these reasons, susceptibility of H. pylori to amoxicillin must be monitored. Epidemiology of resistance Resistance to macrolides The frequency of resistance to macrolides varies from country to country and seems to parallel the use of this therapeutic class to treat other infections, mainly respiratory tract infections in the past. There is a north-south gradient. In Scandinavia where macrolides have rarely been used, the level of H. pylori resistance remains very low while the rate is 10-15% in Southern Europe. There is a tendency towards an increase in resistance in countries where macrolides have recently been introduced. In Belgium, for example, the resistance rate increased from 2.2% in 1990 to 11.1% in It is, therefore, mandatory to have a surveillance of H. pylori resistance to macrolides. Resistance to nitroimidazoles A marked difference has been found between the rate of resistance to nitroimidazoles in developed and developing countries. This difference 210 British Medial Bulletin 1998;54 (No. 1)
5 Antibiotic resistance may be linked to the high level of general use of metronidazole in developing countries, because these countries are mostly tropical countries and this inexpensive drug is commonly used to treat parasitic infections such as amoebiasis. Resistance rates can be as high as 80-90% in developing countries, as reported in Africa (Burkina Faso, Zaire). In developed countries, the rate of resistance ranged from 10-50% in a European multicenter study in The cause of this resistance may also be linked to the use of these compounds for genital infections, especially trichomonasis and, therefore, strains isolated from women are more likely to be resistant than strains isolated from men 18. Another possible cause may be the use of these compounds to treat dental infections. There is a trend towards an increased rate of resistance in developed countries. This may be due to an increased use of these compounds to treat H. pylori infection, because resistant organisms can easily emerge. However, this trend may not be of the magnitude suspected. Indeed, there are problems with regard to the technique used to detect this resistance. In our experience only MICs determined by agar dilution, and not Etest, correlate with the clinical outcome in clinical trials 19. Resistance to fluoroquinolones There have been very few surveys concerning resistance to fluoroquinolones. This resistance is usually reported to be less than 1%. Up until now, fluoroquinolones have been used mostly to treat severe infections in hospital settings and not in the community as is the case for macrolides. When they are used, the treatment lasts for a very short period. Hence, we can conclude that exposure to fluoroquinolones has been limited. Problems observed during the initial treatment for H. pylori These problems concern the possible existence of 'primary' resistance to the compound administered, as well as the possible occurrence of a secondary resistance to the treatment prescribed, both of which can lead to a treatment failure. 'Primary' resistance This is always the consequence of previous treatment with the antibiotic considered, even if the patient has no recollection of previously taking the drug. British Medical Bulletin 1998;54 (No. 1) 211
6 Helicobacter infection Eradication rate (% 100, Fig. 1 Estimated success rate with the triple therapy omeprazoledarithromycinamoxicillin according to the rate of resistance of H. pylori to clarithromycin Resistance rate to clarithromycin (%) The Maastricht consensus report states that susceptibility testing is not mandatory before prescribing the initial treatment 20. The treatment will then be 'probabilistic' and, therefore, must be based on epidemiological data of resistance, either national, or better yet regional. It is currently accepted that, with a resistance rate of H. pylori less than 15% to clarithromycin and less than 30% to metronidazole, it is still reasonable to use these drugs. It must be kept in mind that when there is resistance to one compound, a certain efficacy will come from the other compound. For instance, amoxicillin as the only antibiotic associated with an antisecretory drug which can lead to a 50% success rate and the rate increases to 70% for clarithromycin. The experted success rates according to the rate of resistance to clarithromycin for the omeprazole-amoxicillin-clarithromycin treatment are presented in Figure 1 and according to the rate of resistance Eradication rate (% Fig. 2 Estimated success rate with the triple therapy omeprazoleclarithromycinmetronidazole according to the rate of resistance of H. pylori to metronidazole Resistance rate to metronidazole (%) 212 British Medical Bulletin 1998,54 (No. 1)
7 Antibiotic resistance to metronidazole for the omeprazole-clarithromycin-metronidazole treatment are presented in Figure 2. These expected rates are based on the results of different clinical trials performed in Europe, i.e. ACT and MACH V 2. Secondary resistance Since the resistances concerned are acquired by mutation, it is important that the antibiotics always be present in sufficient quantities at the site of the infection to avoid the emergence of resistance. It is mandatory always to prescribe two antibiotics and to explain carefully to the patient that the compounds must be taken together and without interruption until the end of the 7 day period. Compliance to treatment is a key factor in preventing the occurrence of resistant strains. Problems occurring after failure of initial therapy Failure or eradication will be noticed either by a relapse of symptoms or by a positive test for H. pylori during post-therapy follow-up. Except under special conditions, i.e. gastric ulcer and gastric lymphoma, followup is performed by a [ 13 C]-urea breath test. This test is very specific and its sensitivity post-treatment is higher than 90%. Susceptibility testing of H. pylori to antibiotics In the event of a positive result, testing the susceptibility of H. pylori to antibiotics before prescribing a new eradication treatment is recommended. This is undoubtedly the main reason motivating H. pylori culture. H. pylori is a fragile and slow growing bacterium so it is advisable to refer to specialized laboratories for its culture. With regards to susceptibility testing, all techniques can be used for macrolides while the breakpoint method (8 mg/1) can be recommended for metronidazole and the Etest for amoxicillin. A delay of several days is needed in all cases before obtaining results. Management after failure of a first eradication therapy It is not possible to find answers to this question in the literature, because no trial has yet been performed. However, because cases of failure to eradicate H. pylori are becoming more frequent, such studies British Medical Bulletin 1998;54 (No. 1) 213
8 Helicobacter infection are urgently required. The approach outlined below is only subjective but is facilitated by knowledge of the susceptibility of H. pylori. If the initial antimicrobials given were clarithromycin and amoxicillin, in the event of clarithromycin resistance, metronidazole should be given. If the initial antimicrobials given were clarithromycin and metronidazole, in the event of clarithromycin resistance, amoxicillin should be given; and if there is a metronidazole resistance, amoxicillin can also be used. However, the situation becomes more complicated if the bacterium is resistant to both clarithromycin and metronidazole. The results of one unpublished trial indicate that the combination of amoxicillinmetronidazole is more effective when the dose of metronidazole is increased to 3 x 500 mg/day. Furthermore, it is advisable to increase the duration of treatment from 7 to 10 days. Other combinations, i.e. amoxicillin-tetracycline and amoxicillinciprofloxacin, should also be considered. Quadruple therapy may also be a good alternative. It consists of adding a proton pump inhibitor to standard triple therapy: bismuth salts-tetracycline-metronidazole 23. A new compound, ranitidine bismuth citrate (RBC), combines an antisecretory drug, ranitidine, and an antibacterial drug, bismuth salts, in one molecule. In association with clarithromycin for 2 weeks, RBC achieves eradication rates similar to proton pump inhibitor-based eradication regimens. When combined with two antibiotics, a quadruple therapy is then achieved and this combination given for 7 days may lead to high eradication rates 24. In case of failure without resistance, the same combination can be given a second time but for 2 weeks instead of 1 week, while stressing the importance of compliance. Conclusion In conclusion, H. pylori resistance to antibiotics is the first cause of failure of current eradication regimens. We can expect progress in the field of susceptibility testing, e.g. standardisation of the procedures and development of rapid tests. The main progress will, however, come from using simpler regimens to which H. pylori will not develop resistance. Nitazoxanide, a nitrothiazole compound similar to metronidazole which has this characteristic, is currently under study. Knowledge of the entire sequence of the H. pylori genome should permit the development of drugs which would target specifically vital functions of H. pylori in the near future. 214 British Medical Bulletin 1998;54 (No. 1)
9 Antibiotic resistance References 1 Van der Hulst RWM, Keller JJ, Rauws EAJ et al. Treatment of Helicobacter pylon infection: a review of the world Literature. Helicobacter 1996; 1: Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997; 11 (Suppl 1): Occhialini A, Urdaci M, Doucet-Populaire F et al. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997; 41: Versalovic J, Shortndge D, Kibler K et al. Mutations in 23S rrna are associated with clanthromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: Debets-Ossenkopp YJ, Sparrius M, Kusters JG et al. Mechanism of clanthromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett 1996; 142: Szczebara F, Dhaenens L, Vincent P et al. Evaluation of rapid molecular detection of clanthromycin resistance in Helicobacter pylori. Eur ] Clin Microbiol Infect Dis 1997; 16: Stone GG, Shortndge D, Versalovic J et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rrna gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 1997; 41: 712^ 8 Pina M, Occhialini A, Monteiro L et al. Rapid detection of point mutations associated with macrolide resistance in Helicobacter pylori using the Gen-eti-k DEIA hybridization kit. Gut 1997; 41(Suppl 1): A75 9 Smith MA, Edwards DI. The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori. ] Antimicrob Chemother 1995; 36: Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. ] Antimicrob Chemother 1992; 29: Smith MA, Edwards DI. Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter pylori to mtroheterocyclic drugs. / Anttmicrob Chemother 1995; 35: Van Zwet AA, Thijs JC, de Graaf B. Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains. Antimicrob Agents Chemother 1995; 39: Hoffman PS, Goodwin A, Johnsen et al. Metabolic activities of metronidazole-sensitive and - resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. / Bacteriol 1996; 178: Moore RA, Beckthold B, Wong S et al. Nucleotide sequence of the gyrh gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995; 39: Midolo PD, Korman MG, Turnbridge JD et al. Helicobacter pylori resistance to tetracycline. Lancet 1996; 347: Dore MP, Sepulveda AR, Mura I et al. Explanation for variability of omeprazole-amoxicillin therapy? Tolerance of H. pylori to amoxjcilhn. Gastroenterology 1997; 112: A de Koster E, Cozzoli A, Vandenborre C et al. H. pylori resistance to macrolides increases, to imidazoles remains stable. Gastroenterology 1997; 112: A99 18 Glupczynski Y, the European Study Group on Antibiotic Susceptibility of H. pylori. Results of a multicentre European survey in 1991 of metronidazole resistance in H. pylori. Eur J Clin Microbiol Infect Dis 1992; 11: Bouchard S, Birac C, Lamouliatte H et al. Correlation between the M1CS of metronidazole on H. pylori strains and the outcome of a lansoprazole-amoxicilline-metronidazole therapy. Gut 1996; 39 (Suppl 2): 1A05 20 Malfertheiner P, Megraud F, O'Morain C et al. Current European concepts in the management of Helicobacter pylori infection - the Maastricht consensus report. Eur] Gastroenterol Hepatol 1997; 9: 1-2 British Medial Bulletin 1998;54 (No. 1) 215
10 Helicobacter infection 21 Wurzer H, Rodrigo L, Stamler D et al. Short-course therapy with amoxicillin-clarithromycin triple for 10 days (ACT-10) eradicates H. pylori and heals duodenal ulcer. Aliment Pharmacol Ther 1997; 11: Megraud F, Lehn N, Lind T et al. The MACH 2 study. Helicobacter pylori resistance to antimicrobiol agents and its influence on clinical outcome. Gastroenterology 1997; 112: A de Boer W, Driessen W, Jansz A et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: Savarino, Mansi C, Mele MR et al. A new one-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. Aliment Pharmacol Ther 1997; 11: British Medical Bulletin 1998;54 (No. 1)
The discovery of the key role of Helicobacter pylori
GASTROENTEROLOGY 1998;115:1278 1282 Epidemiology and Mechanism of Antibiotic Resistance in Helicobacter pylori FRANCIS MÉGRAUD Laboratoire de Bactériologie, Hôpital Pellegrin, Université Victor Segalen,
More information/01/$ DOI: /AAC Copyright 2001, American Society for Microbiology. All Rights Reserved.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2001, p. 1500 1504 Vol. 45, No. 5 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.5.1500 1504.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationWhat is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationThe role of antisecretory drugs in the treatment of Helicobacter pylori infection
Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 21 25. The role of antisecretory drugs in the treatment of Helicobacter pylori infection W. L. PETERSON Department of Internal Medicine, University of Texas
More informationRapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands.
Chapter 2 Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands. E.J.van der Wouden 1, A.A.van Zwet 2, J.C.Thijs 1, G.D.C.Vosmaer 3, J.A.J.Oom 4, A.de Jong
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationTreatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationPrevpac Pylera Omeclamox-Pak
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,
More informationRates of clarithromycin resistance in Helicobacter pylori sampled from healthy subjects in Cheonan, Korea
Rates of clarithromycin resistance in Helicobacter pylori sampled from healthy subjects in Cheonan, Korea Young Sam Yuk 1, Ga-Yeon Kim 2 1. Department of Biomedical Laboratory Science, Dankook University
More informationThe annual incidence of peptic ulcer disease in developed
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2003;1:273 278 Pretreatment Antimicrobial Susceptibility Testing Is Cost Saving in the Eradication of Helicobacter pylori MARCO ROMANO,* RICCARDO MARMO, ANTONIO
More informationRole of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication
Aliment Pharmacol Ther 2000; 14: 1639±1643. Role of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication S. TORACCHIO*, L. CELLINI, E.DICAMPLI, G.CAPPELLO*,M.G.MALATESTA*,A.FERRI*,
More informationAntibiotic Susceptibility of Helicobacter pylori Clinical Isolates: Comparative Evaluation of Disk-Diffusion and E-Test Methods
CURRENT ROBIOLOGY Vol. 53 (2006), pp. 329 334 DOI: 10.1007/s00284-006-0143-1 Current Microbiology An International Journal ª Springer Science+Business Media, Inc. 2006 Antibiotic Susceptibility of Helicobacter
More informationPerspectives from Viet Nam
International Symposium I (Management of antibiotics-resistant Helicobacter pylori infection) Perspectives from Viet Nam Vu Van Khien 1,HoDangQuyDung 2, Tran Thanh Binh 2 1 Department of GI Endoscopy,
More informationTreating H. pylori in 2016
Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes
More informationEfficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection
ORIGInAL PAPERs Efficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection Antonio Tursi 1, Marcello Picchio 2, Walter Elisei
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationORIGINAL ARTICLE /j X x
ORIGINAL ARTICLE 10.1111/j.1198-743X.2004.00779.x Laboratory handling of Helicobacter pylori critically influences the results of in-vitro metronidazole resistance determination T. H. Henriksen 1, F. Lerang
More informationEradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin
CASE REPORT Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin Takahisa Furuta 1, Mitsushige Sugimoto 2, Mihoko Yamade
More informationEfficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2012.15.4.237 Pediatric Gastroenterology, Hepatology & Nutrition 2012 December 15(4):237-242 Original Article PGHN Efficacy of Proton Pump
More informationHelicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens
Helicobacter ISSN 1523-5378 Filipec Blackwell Oxford, HEL 1083-4389 1523-5378 Journal XXX Original H. 2008 pylori Kanizaj compilation The UK Eradication Publishing Article Authors et al. Ltd 2008 Therapy
More informationOriginal article J Bas Res Med Sci 2015; 2(4):45-50.
Comparison between the effectiveness of Furazolidone and Clarithromycin on eradication of helicobacter pylori among patients with peptic ulcer Asghar Rahmani 1, Ali Jafari Haidarloo 2, Hoda Mabrokzadeh
More informationOne-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers
Aliment Pharmacol Ther 1997; 11: 89 93. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers J. LABENZ*, J.-P. IDSTRO M, B. TILLENBURG*,
More informationMulticenter Survey of Routine Determinations of Resistance of Helicobacter pylori to Antimicrobials over the Last 20 Years (1990 to 2009) in Belgium
JOURNAL OF CLINICAL MICROBIOLOGY, June 2011, p. 2200 2209 Vol. 49, No. 6 0095-1137/11/$12.00 doi:10.1128/jcm.02642-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationAntibiotic susceptibilities of Helicobacter pylori strains isolated in the Province of Alberta
ORIGINAL ARTICLE Antibiotic susceptibilities of Helicobacter pylori strains isolated in the Province of Alberta Diane E Taylor PhD 1, Qin Jiang MSc 1, Richard N Fedorak MD 2 DE Taylor, Q Jiang, RN Fedorak.
More informationProton pump inhibitor (proton pump inhibitor)-based triple therapies using clarithromycin in combination SUMMARY INTRODUCTION
Aliment Pharmacol Ther 2003; 18: 799 804. doi: 10.1046/j.1365-2036.2003.01764.x Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter
More informationTreatment for H. pylori Infection. New Challenges With Antimicrobial Resistance
CLINICAL REVIEW Treatment for H. pylori Infection New Challenges With Antimicrobial Resistance Nimish Vakil, MD, FACP, FACG, AGAF, FASGE* and Dino Vaira, MDw Abstract: The treatment of Helicobacter pylori
More informationTreatment of H. pylori Infection: The Reality
YALE JOURNAL OF BIOLOGY AND MEDICINE 71 (1998), pp. 119-124. Copyright 1999. All rights reserved. Treatment of H. pylori Infection: The Reality Nimish Vakil University of Wisconsin Medical School, Milwaukee
More informationReceived 17 August 2010/Returned for modification 7 December 2010/Accepted 16 December 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAY, Mar. 2011, p. 1123 1129 Vol. 55, No. 3 0066-4804/11/$12.00 doi:10.1128/aac.01131-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Genotypic
More informationFailure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates
cp60392 Module 1 Journal of Clinical Pathology 28/8/08 12:38:20 Topics: ; Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical
More informationManagement of H. pylori Resistance
Management of H. pylori Resistance Manfred Kist, Erik Glocker, Nicole Wüppenhorst, Beate Hobmaier National Reference Centre for Helicobacter pylori Institute of Medical Microbiology and Hygiene Freiburg,
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationPhenotypic and genotypic correlation as expressed in Helicobacter pylori resistance to clarithromycin and fluoroquinolones
DOI 10.1186/s13099-017-0198-5 Gut Pathogens RESEARCH Open Access Phenotypic and genotypic correlation as expressed in Helicobacter pylori resistance to clarithromycin and fluoroquinolones Dana Binyamin
More informationThe effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori
Aliment Pharmacol Ther 1999; 13: 667±673. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori A. PILOTTO*, G. LEANDRO, M. FRANCESCHI*, M. RASSUà,
More informationAntibiotic resistance is now often understood at the VIEWPOINTS IN DIGESTIVE DISEASES
GASTROENTEROLOGY 1998;115:1272 1277 VIEWPOINTS IN DIGESTIVE DISEASES Antibiotic Resistance in Helicobacter pylori: Implications for Therapy DAVID Y. GRAHAM Department of Medicine, Veterans Affairs Medical
More informationProtein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8
Protein Synthesis Inhibitors Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8 These drugs selectively inhibit bacterial protein synthesis. The selectivity is due to the differences between bacterial and human
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationThree-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study
Aliment Pharmacol Ther 2001; 15: 843±849. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study B. C. Y. WONG*, W. H. WANG*, W.M.WONG*,G.K.K.LAU*,F.M.Y.FUNG*,N.N.S.KUNGà,
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:10.22034/APJCP.2017.18.4.927 Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole RESEARCH ARTICLE Outcomes of a Randomized Controlled Trial Comparing Modified High Dose
More informationHeterogeneity in Susceptibility to Metronidazole among Helicobacter pylori Isolates from Patients with Gastritis or Peptic Ulcer Disease
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1996, p. 2158 2162 Vol. 34, No. 9 0095-1137/96/$04.00 0 Copyright 1996, American Society for Microbiology Heterogeneity in Susceptibility to Metronidazole among
More informationTitle. Author(s)Kato, Mototsugu. Issue Date Doc URL. Type. Note. File Information.
Title Effects of lansoprazole plus amoxycillin on the cure Author(s)Kato, Mototsugu Issue Date 1996-12-25 Doc URL http://hdl.handle.net/2115/32629 Type theses (doctoral) Note 共著者あり 共著者名 :Asaka Masahiro,
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationReview article: the global emergence of Helicobacter pylori antibiotic resistance
Alimentary Pharmacology and Therapeutics Review article: the global emergence of Helicobacter pylori antibiotic resistance I. Thung*,1, H. Aramin*,1, V. Vavinskaya*, S. Gupta,J.Y.Park, S. E. Crowe & M.
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationArab Journal of Gastroenterology
Arab Journal of Gastroenterology 14 (2013) 1 5 Contents lists available at SciVerse ScienceDirect Arab Journal of Gastroenterology journal homepage: www.elsevier.com/locate/ajg Original Article Penbactam
More information(Index words: Clarithromycin, compliance, efficacy, tinidazole and omeprazole therapy)
Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in a Sri Lankan population: a randomised, controlled study HA de Silva 1, J Hewavisenthi 2, A Pathmeswaran
More informationLow Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial
Global Journal of Health Science; Vol. 7, No. 1; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Low Dose Furazolidone for Eradication of H- pylori Instead of
More informationPharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Record Status This is a critical abstract of an economic evaluation that
More informationThe treatment of helicobacter pylori infection and its sequelae with emphasis on nitroimidazole resistance Wouden, Egbert-Jan van der
University of Groningen The treatment of helicobacter pylori infection and its sequelae with emphasis on nitroimidazole resistance Wouden, Egbert-Jan van der IMPORTANT NOTE: You are advised to consult
More informationCase 4: Peptic Ulcer Disease. Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie
Case 4: Peptic Ulcer Disease Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie Case 4: PUD Problem List: 1. Peptic Ulcer Disease SOAP Note: S Patient is complaining of abdominal pain
More informationThe term biofilm describes the structurally complex bacterial BRIEF COMMUNICATION
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:817 820 BRIEF COMMUNICATION Biofilm Demolition and Antibiotic Treatment to Eradicate Resistant Helicobacter pylori: A Clinical Trial GIOVANNI CAMMAROTA,*
More informationHigh prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong
Title High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong Author(s) Wang, WH; Wong, BCY; Mukhopadhyay, AK; Berg, DE; Cho, CH; Lai, KC;
More informationLow-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients
Blackwell Science, LtdOxford, UKJGHJournal of Gastroenterology and Hepatology0815-93192005 Blackwell Publishing Asia Pty Ltd206935940Original ArticleLow-dose rabeprazole-based triple therapywm Wong et
More information헬리코박터제균요법에있어서 CYP2C19 유전형이판토프라졸과라베프라졸포함치료법에미치는영향. Introduction 울산대학교의과대학서울아산병원소화기내과
The Korean Journal of Helicobacter and Upper Gastrointestinal Research Vol. 8, No. 1, 15-19, July 2008 Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: Comparison between Pantoprazole
More informationEDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.
More informationAnalysis of Gene Mutations Associated with Antibiotic Resistance in Helicobacter pylori Strains Isolated from Korean Patients
ORIGINAL ARTICLE ISSN 1738-3331, http://dx.doi.org/10.7704/kjhugr.2014.14.2.95 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2014;14(2):95-102 Analysis of Gene Mutations Associated
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationHelicobacter pylori resistance in the Netherlands: a growing problem?
ORIGINAL ARTICLE Helicobacter pylori resistance in the Netherlands: a growing problem? R. Ruiter 1,2 *, H.F. Wunderink 3, R.A. Veenendaal 5, L.G. Visser 4, M.G.J. de Boer 4 Departments of 1 Internal Medicine,
More informationYang K. Chen, MD* Prahalad Jajodia, MD Lino DeGuzman, MD Shahid A. Khan, MD Vaman S. Jakribettuu, MD*
Randomized Controlled Trial Comparing Proton Pump Inhibitor- Based Eradication Regimen versus Low-Cost Eradication Regimen for Patients with Helicobacter pylori with Uninvestigated Dyspepsia Yang K. Chen,
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationA Multi-Criteria Decision Making Model for Treatment of Helicobacter pylori Infection in Children
HK J Paediatr (new series) 2012;17:237-242 A Multi-Criteria Decision Making Model for Treatment of Helicobacter pylori Infection in Children A ERJAEE, M BAGHERPOUR, S RAZEGHI, SM DEHGHANI, MH IMANIEH,
More informationGASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA
GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority
More informationHelicobacter pylori eradication an update on the latest therapies
Helicobacter pylori eradication an update on the latest therapies Author Yaxley, Julian, Chakravarty, Bhaskar Published 2014 Journal Title Australian Family Physician Copyright Statement 2014 Australian
More informationDistribution of Antibiotic MICs for Helicobacter pylori Strains over a 16-Year Period in Patients from Seoul, South Korea
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4843 4847 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4843 4847.2004 Copyright 2004, American Society for Microbiology. All Rights
More informationMacrolides, Clindamycin & Ketolides Polymyxins
Macrolides, Clindamycin & Ketolides Polymyxins Kwan Soo Ko Macrolides - Erythromycin - Azithromycin - Clarithromycin Lincosamides - Lincomycin - Clindamycin Unrelated chemically But, many similar biological
More informationRisk of Development of In Vitro Resistance to Amoxicillin, Clarithromycin, and Metronidazole in Helicobacter pylori
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1222 1228 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Risk of Development of In Vitro Resistance to Amoxicillin,
More informationResearch Article Molecular Detection of Antibiotic Resistance in South African Isolates of Helicobacter pylori
Gastroenterology Research and Practice Volume 2013, Article ID 259457, 6 pages http://dx.doi.org/10.1155/2013/259457 Research Article Molecular Detection of Antibiotic Resistance in South African Isolates
More informationSusceptibility of Helicobacter Pylori to Antibiotics: a Study of Prevalence in Patients with Dyspepsia in Quito, Ecuador
DOI: https://doi.org/.5/57.7 Susceptibility of Helicobacter Pylori to Antibiotics: a Study of Prevalence in Patients with Dyspepsia in Quito, Ecuador Jorge Reyes Ch., Katherine Guzmán, Eduardo Morales,
More informationRECENT ADVANCES IN CLINICAL PRACTICE HPYLORIANTIBIOTIC RESISTANCE: PREVALENCE, IMPORTANCE, AND ADVANCES IN TESTING
1374 RECENT ADVANCES IN CLINICAL PRACTICE HPYLORIANTIBIOTIC RESISTANCE: PREVALENCE, IMPORTANCE, AND ADVANCES IN TESTING c PREVALENCE Correspondence to: F Mégraud, Laboratoire de Bactériologie, Hôpital
More informationRECENT ADVANCES IN CLINICAL PRACTICE HPYLORIANTIBIOTIC RESISTANCE: PREVALENCE, IMPORTANCE, AND ADVANCES IN TESTING
1374 RECENT ADVANCES IN CLINICAL PRACTICE HPYLORIANTIBIOTIC RESISTANCE: PREVALENCE, IMPORTANCE, AND ADVANCES IN TESTING FMégraud c PREVALENCE T Gut 2004; 53:1374 1384. doi: 10.1136/gut.2003.022111 he discovery
More informationA Pilot Study of Helicobacter pylori Eradication Using a Polymerase Chain Reaction-based Test for Clarithromycin Resistance
ORIGINAL ARTICLE ISSN 1738-3331, https://doi.org/10.7704/kjhugr.2017.17.4.200 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017;17(4):200-207 A Pilot Study of Helicobacter pylori
More informationHelicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師
Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Hp : Helicobacter pylori Part 1. Pathophysiology and immune response Pathogenesis of Hp infection Part 2. Clinical manifestation Part 3. Dx tests for
More informationCost-effectiveness analysis of different strategies for treating duodenal ulcer Badia X, Segu J L, Olle A, Brosa M, Mones J, Ponte L G
Cost-effectiveness analysis of different strategies for treating duodenal ulcer Badia X, Segu J L, Olle A, Brosa M, Mones J, Ponte L G Record Status This is a critical abstract of an economic evaluation
More informationHybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial
ORIGINAL ARTICLE Annals of Gastroenterology (2018) 31, 1-6 Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial
More informationMaastricht Ⅴ /Florence
2016 21 10 577 Maastricht Ⅴ /Florence 200001 2015 10 8 9 Maastricht V 1 / 2 3 4 / 5 Maastricht Ⅴ Interpretation of Management of Helicobacter pylori Infection the Maastricht Ⅴ / Florence Consensus Report
More informationA Heaney, J S A Collins, RGPWatson, R J McFarland, K B Bamford, T C K Tham
186 Royal Victoria Hospital, Belfast, A Heaney J S A Collins Department of Medicine, Queen s University, Belfast, RGPWatson Ulster Hospital, Dundonald, R J McFarland T C K Tham Department of Microbiology
More informationNicola C. Elviss, 1,2 Robert J. Owen, 1 Aodhan Breathnach, 3 Catherine Palmer 4 and Nandini Shetty 4 INTRODUCTION
Journal of Medical Microbiology (2005), 54, 567 574 DOI 10.1099/jmm.0.45896-0 Helicobacter pylori antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnically diverse populations
More informationDisclosures. Co-founder and Chief Science Officer, TechLab
H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the
More informationAntimicrobial Resistance of Helicobacter pylori Clinical Strains in the Last 10 Years
Polish Journal of Microbiology 2009, Vol. 58, No 4, 301 305 ORIGINAL PAPER Antimicrobial Resistance of Helicobacter pylori Clinical Strains in the Last 10 Years EWA ANDRZEJEWSKA, ANDRZEJ SZKARADKIEWICZ*,
More informationStudy population The study population comprised hypothetical patients with gastric and duodenal ulcer.
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan Ikeda S, Tamamuro T, Hamashima C, Asaka M Record Status This is a critical
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/59359
More informationlife-threatening infections
Vancomycin Vancomycin has become increasingly important in the treatment of life-threatening infections. MRSA infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) infections Enterococcal
More informationPEER REVIEW HISTORY ARTICLE DETAILS
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationORIGINAL INVESTIGATION. Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting
ORIGINAL INVESTIGATION Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting M. Brian Fennerty, MD; David A. Lieberman, MD; Nimish Vakil, MD; Nathan Magaret; Douglas O. Faigel,
More informationSURVEY IN IRAN OF CLARITHROMYCIN RESISTANCE IN HELICOBACTER PYLORI ISOLATES BY PCR-RFLP
SURVEY IN IRAN OF CLARITHROMYCIN RESISTANCE IN HELICOBACTER PYLORI ISOLATES BY PCR-RFLP Nourkhoda Sadeghifard 1, Teimour Seidnazari 1, Sobhan Ghafourian 1,3, Mohammad Soleimani 2, Abbas Maleki 1, Mostafa
More informationTreating Helicobacter pylori effectively while minimizing misuse of antibiotics
REVIEW AKIKO SHIOTANI, MD, PhD Professor, Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan EDUCATIONAL OBJECTIVE: Readers will treat Helicobacter pylori infections according to
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationSystematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure
Alimentary Pharmacology & Therapeutics Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure J. P. GISBERT & F. DE LA MORENA Department of
More informationClarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis
ORIGINAL ARTICLE 2018 Jun 14. [Epub ahead of print] https://doi.org/10.3904/kjim.2018.054 Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis
More information